Previous Article | Next Article 
J Virol, May 1998, p. 4192-4204, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
The Envelope Protein Encoded by the A33R Gene Is
Required for Formation of Actin-Containing Microvilli and
Efficient Cell-to-Cell Spread of Vaccinia Virus
Rachel L.
Roper,
Elizabeth J.
Wolffe,
Andrea
Weisberg, and
Bernard
Moss*
Laboratory of Viral Diseases, National
Institutes of Allergy and Infectious Diseases, Bethesda, Maryland
20892-0445
Received 1 December 1997/Accepted 6 February 1998
 |
ABSTRACT |
The vaccinia virus (VV) A33R gene encodes a highly conserved 23- to
28-kDa glycoprotein that is specifically incorporated into the viral
outer envelope. The protein is expressed early and late after
infection, consistent with putative early and late promoter sequences.
To determine the role of the protein, two inducible A33R mutants were
constructed, one with the late promoter and one with the early and late
A33R promoter elements. Decreased A33R expression was associated with
small plaques that formed comets in liquid medium. Using both an
antibiotic resistance gene and a color marker, an A33R deletion mutant,
vA33
, was isolated, indicating that the A33R gene is not essential
for VV replication. The plaques formed by vA33
, however, were tiny,
indicating that the A33R protein is necessary for efficient
cell-to-cell spread. Rescue of the large-plaque phenotype was achieved
by inserting a new copy of the A33R gene into the thymidine kinase
locus, confirming the specific genetic basis of the phenotype. Although
there was a reduction in intracellular virus formed in cells infected
with vA33
, the amount of infectious virus in the medium was
increased. The virus particles in the medium had the buoyant density of
extracellular enveloped viruses (EEV). Additionally, amounts of vA33
cell-associated extracellular enveloped viruses (CEV) were found to be
normal. Immunogold electron microscopy of cells infected with vA33
demonstrated the presence of the expected F13L and B5R proteins in
wrapping membranes and EEV; however, fully wrapped vA33
intracellular enveloped viruses (IEV) were rare compared to partially
wrapped particles. Specialized actin tails that propel IEV particles to the periphery and virus-tipped microvilli (both common in
wild-type-infected cells) were absent in cells infected with vA33
.
This is the first deletion mutant in a VV envelope gene that produces
at least normal amounts of fully infectious EEV and CEV and yet has a
small-plaque phenotype. These data support a new model for VV spread,
emphasizing the importance of virus-tipped actin tails.
 |
INTRODUCTION |
Vaccinia virus (VV), the most
intensively studied member of the Orthopoxvirus genus of the
Poxviridae, is closely related to variola and monkeypox
viruses, the causative agents of pandemic smallpox and a smallpox-like
disease in Zaire, respectively (17, 35). VV, previously used
as a smallpox vaccine, is a vector in recombinant vaccine strategies to
prevent numerous infectious diseases and to treat cancer
(33, 34). The characteristic features of orthopoxviruses are
the following: a large, nearly 200,000-bp genome; a cytoplasmic
site of replication; regulated early, intermediate, and late gene
expression; and a complex mode of assembly involving multiple viral
membranes (33). The latter aspect of VV replication is the
subject of this study.
The first viral structures, visible by electron microscopy of infected
cells, are crescent-shaped membranes associated with dense granular
material (8). These structures evolve into spherical particles containing nucleoids and then into brick-shaped intracellular mature virions (IMV). IMV have two closely apposed outer membranes (48), comprise the majority of intracellular virus
particles, and are infectious upon disruption of infected cells. Some
IMV are destined to form intracellular enveloped viruses (IEV) by acquisition of two additional membrane layers from the trans-Golgi cisternae (23, 27, 43). The four membrane IEV may be
propelled by actin tails to the cell periphery to form specialized
microvilli (7, 22, 24, 49). The outermost viral membrane of
IEV fuses with the plasma membrane (1), and the externalized
particles, with three remaining membranes, remain attached to the cell
surface as cell-associated extracellular enveloped viruses (CEV) or are released as extracellular enveloped viruses (EEV) (3, 27, 32, 39,
43). The CEV have been thought to mediate local cell-to-cell
spread, whereas the EEV may provide long-range transmission.
Since enveloped virus particles are responsible for the spread of
infection (1, 2, 5, 38, 52), the formation and function of
the IEV, CEV, and EEV are of considerable interest. The proteins
incorporated into the outer envelope are encoded by at least six genes,
namely, the A56R (40, 46), F13L (2, 25), B5R
(14, 29), A36R (36), A34R (11, 31),
and A33R (41) genes. Information regarding the roles of the
individual envelope proteins has been obtained by deleting or
repressing the expression of the cognate genes. Mutants with a deletion
of the F13L, B5R, A36R, or A34R gene produce small plaques in vitro and
where tested are severely attenuated in vivo (2, 11, 15, 28, 31,
36, 44, 54). Since these mutations have little effect on IMV
formation, IMV must not mediate efficient cell-to-cell spread. The
small-plaque phenotype, however, appears to have several different
causes. Deletion of the B5R or F13L gene severely inhibits formation of
IEV and extracellular particles because of a defect in wrapping
(2, 15, 54). By contrast, EEV formation is increased when
the A34R gene is deleted (31, 55) and moderately reduced
when the A36R gene is deleted (36). The small-plaque
phenotype of the A34R mutant has been attributed to an 80% decrease in
the specific infectivity of mutant EEV (31) and to the
absence of actin tails and specialized microvilli (55), although the relative contributions of the two effects are unclear.
The A33R gene was recently shown to encode a type II integral membrane
protein found in EEV but not IMV (41). The A33R gene is
highly conserved in all orthopoxviruses (41, 42), and a homolog is present in distantly related Molluscum contagiosum virus
(45), suggesting that it has an important role. Despite its
conservation in poxviruses, the A33R gene product shows little homology
to other proteins, precluding any functional insights. Here, we
describe the effects of mutations in the promoter or coding regions of
the A33R gene on the VV life cycle. A severe reduction in cell-to-cell
spread was attributed to a defect in the formation of actin tails and
specialized, virus-tipped microvilli.
 |
MATERIALS AND METHODS |
Cells and antibodies.
VV stocks were prepared in HeLa cells
as described previously (12); BS-C-1 cells served for plaque
assays, immunoprecipitations, and Western blotting; and
RK13 cells were used to propagate VV for CsCl purification.
Cells were grown in Eagle minimal essential medium (EMEM) with 10%
fetal bovine serum, and infections were carried out in EMEM with 2.5%
fetal bovine serum. For titrations of VV and analysis of plaque size,
monolayers were fixed and stained with 0.1% crystal violet in 20%
ethanol. Mouse monoclonal antibody (MAb) 20 (B5R specific) and MAb 4 (A33R specific) have been described before (37, 41). The
F13L peptide RLVETLPENMDFRSDHLTTFEC was injected into rabbits to
prepare anti-37N antibody.
Construction of inducible VV A33R mutants.
DNA segments
containing an intact A33R open reading frame (ORF), a modified
promoter, the Escherichia coli xanthine guanine phosphoribosyl transferase (gpt) gene under the p7.5
promoter, and flanking sequences were constructed by linking together
five pieces of DNA by recombinant PCR (53). The flanking
sequence that included part of the adjacent A32L coding region was
amplified by using the primer pair CCTAATATTGGTACGTGTCTA and
GATTTATTATCAAATTAATTTAC. The gpt gene was
amplified by using a first primer containing sequences of the A32L
promoter region (underlined), namely,
CTAAATTAATTTGATAATAAATCTTAGCGACCGGAGATTGG; the
second primer,
CGACCTTAGTTTTCCATATTTTCACTAATTCCAAACCCACC (used for the virus named 13E14 or vA33full) or
GCCTTCTTTGTTCTCCTCCCACTAATTCCAAACCCACC (for the
virus named 9M2B or vA33late) contained the A33R early or late promoter
(sequence underlined), respectively. The promoter region of A33R was
amplified with AAAATATGGAAAACTAAGGTCG or
GGAGGAGAACAAAGAAGGC to either include or exclude the
putative early promoter, respectively. The other end of the promoter
region was amplified with
GAATTGTGAGCGCTCACAATTCTATTTATGTCACGATGT, containing sequences of the E. coli lac operator
(lacO; underlined). The A33R gene was amplified with primers
GTGAGCGCTCACAATTCACATTTATTATCATGATG containing
sequences of the lacO (underlined) and
AAAATAAATATTAGTTCATTGTT. The six DNA segments (there were
two alternate A33R promoter pieces used) were amplified by PCR
individually, purified by using Promega PCR Preps, and then joined by
recombinant PCR in a stepwise fashion. The final 1,963- and 1,934-bp
PCR products were cloned in a TA vector (Invitrogen, San Diego, Calif.)
and sequenced by using a Prism Dye Deoxy Terminator Cycle Sequencing
Kit (Applied Biosystems, Foster City, Calif.) in conjunction with a
model 373 DNA sequencer (Applied Biosystems). The plasmids were mixed
with
N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl sulfate (DOTAP) (Boehringer Mannheim) and transfected into cells
infected with the recombinant vaccinia virus vlacI (19), which contains the lac repressor (lacI) in the TK
locus. Viruses were grown under semisolid agarose (GIBCO/BRL,
Grand Island, N.Y.) containing mycophenolic acid (MPA; Sigma) for
selection of recombinant virus (16) and 5 mM
isopropyl-
-D-thiogalactopyranoside (IPTG) for induction
of the A33R gene. Viruses were plaque purified three times and
amplified.
Recombinant viral genomes were analyzed by PCR. Primers were chosen so
that they amplified from within the A32L gene
(ATCTGGGTTATAAACGGGTG) to within the A33R gene
(ACCAATCACGCGTTTGCGTT), such that DNA from wild-type (WT) or
inducible viruses would yield PCR products of approximately 400 and
1,250 bp, respectively. PCR (25 cycles) was carried out by standard
procedures using Taq polymerase (Boehringer) with a 50°C
annealing temperature.
Immunoprecipitation and Western blotting.
Immunoprecipitates
and Western blots were made essentially as described previously
(41).
Deletion of the A33R gene.
To create an A33R deletion
mutant, the A33R flanks were amplified by PCR and cloned into the
pZippy neo/GUS vector (47), containing the
neomycin resistance gene (neo) (18) as well as the color marker
-glucuronidase (GUS) (6). The A32L
flanking region was amplified with the primer pair
GCGAAGCTTCCTAATATTGGTACGTGTCTA (HindIII restriction site underlined) and
GCGGTCGACGATTTATTATCAAATTAATTTAG (SalI
restriction site underlined). The A34R flanking region was amplified
with the primer pair GCGGAGCTCTATCACAAGAAGTTAGAAAGT (SacI site underlined) and
GCGAGATCTCATTTTTTGTTGTCACTTGTA (BglII site underlined). The PCR products and vector were digested, purified, ligated (Rapid Ligation Kit; Boehringer Mannheim), and used to transform E. coli (One Shot; Invitrogen), which was selected
on ampicillin plates. The correct sequence of VV-derived DNA was confirmed, and the plasmids were transfected into cells infected with
vA33late and incubated under a geneticin (GIBCO)-containing semisolid
agarose overlay. After 2 days, infected monolayers were overlaid with
medium containing 0.2 mg of
5-bromo-4-chloro-3-indolyl-
-D-glucuronide (X-Glu;
Clontech Laboratories, Palo Alto, Calif.) per ml. Two days later, blue
plaques were picked. After three rounds of plaque purification, the
virus was amplified in six-well plates and viral DNA was analyzed by
PCR. Primers ATCTGGGTTATAAACGGGTG and
AAAATAAATATTAGTTCATTGTT were chosen to amplify from inside
the A32L ORF to the junction of the A33R ORF and A34R promoter, such
that WT DNA would yield a PCR product of 870 bp, the vA33late DNA with
the inserted gpt gene would yield a product of 1,670 bp, and
the knockout vA33
DNA with the neo/GUS genes would yield
a product of 3,270 bp.
Construction of the A33R rescue virus.
The A33R gene was
amplified by PCR using primers with restriction sites for cloning into
the modified pSC11 vector containing TK flanking regions and the
lacZ gene (13). The A33R gene was inserted after
the P7.5 promoter of the vector so that both an early and a late
promoter would regulate transcription. The upstream primer was
CGCGCGTCGACATAAATAACATTTATTATC (SalI
site underlined); the other primer was
CTGAGCGGCCGCATTAGTTCATTGTTTTAACACA
(NotI site underlined). The purified PCR product and
vector plasmid were digested, repurified, and ligated together.
Bacterial colonies were grown on agar plates containing ampicillin.
Plasmids were prepared by using Promega Mini Preps and transfected into
cells infected with vA33
. The infected cells were overlaid with
semisolid plaque medium containing
5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-Gal;
Promega) for detection of recombinant virus containing the
lacZ gene. Blue plaques were picked three times in
succession, and the purified virus was amplified. The viral DNA was
analyzed by PCR for the presence of pSC11 flanking sequences contiguous with the A33R sequence and also for the absence of WT A33R in the A33R
locus. The primer with the A33R promoter sequence was GGAGGAGAACAAAGAAGGC; the other was
AAAATAAATATTAGTTCATTGTT. By using these primers, WT DNA
yielded the predicted 615-bp product. To further confirm that the
viruses were derived from vA33
, infected monolayers were stained
with X-Glu to detect the GUS gene used to replace the A33R gene.
Electron microscopy.
For transmission electron microscopy,
RK13 cells in 60-mm-diameter dishes were infected with VV
at a multiplicity of 10 for 24 h, fixed in 2% glutaraldehyde, and
embedded in Embed-812 (Electron Microscopy Sciences, Fort Washington,
Pa.) or fixed with increasing concentrations of paraformaldehyde and
prepared for immunoelectron microscopy as previously described
(55). Thawed cryosections were incubated with either rabbit
antipeptide antibody to F13L or MAb 20 recognizing the B5R protein
(37). Samples were washed, incubated with gold particles
conjugated to protein A (Department of Cell Biology, Utrecht University
School of Medicine, Utrecht, The Netherlands), and viewed with a
Philips CM 100 electron microscope.
For scanning electron microscopy, HeLa cells were grown on coverslips,
infected with VV at a multiplicity of 10, and fixed
and prepared for
analysis on an Amray 1820D microscope at an accelerating
voltage of 15 kV as described previously (
55).
One-step growth curves.
Confluent BS-C-1 or RK13
cell monolayers in six-well plates were infected with VV at a
multiplicity of 10 for 2 h. The inocula were removed, the cells
were washed, and fresh medium was added. At intervals, the medium from
an individual well was harvested and centrifuged at 1,800 × g for 5 min to pellet detached cells. The resulting cell
pellet was combined with infected cells that had been scraped from the
plate into 1 ml of fresh medium. Cells were frozen and thawed three
times and sonicated. Viruses from the media and cells were titrated in
duplicate on BS-C-1 cell monolayers.
Virus purification.
Wrapped and unwrapped virus particles
were purified on the basis of their buoyant densities in CsCl as
described previously (41).
Syncytium formation.
Confluent BS-C-1 cell monolayers were
infected at a multiplicity of 10 for 2 h, washed, and incubated in
medium for an additional 10 h as described before (2,
54). Cells were washed and treated with fusion buffer
[phosphate-buffered saline with 10 mM
2-(N-morpholino)ethanesulfonic acid and 10 mM HEPES] at pH
5.5 or 7.4 for 2 min at 37°C. Afterwards, fusion buffer was replaced
with medium and the cells were incubated at 37°C and then observed by
phase-contrast microscopy.
Immunofluorescence microscopy.
Fluorescence microscopy was
performed as described previously (55). Infected HeLa cell
monolayers on coverslips were washed with phosphate-buffered saline,
fixed in 3% paraformaldehyde, and permeabilized with 0.05% saponin
(Calbiochem, San Diego, Calif.). Actin filaments were visualized with
fluorescein isothiocyanate (FITC)-conjugated phalloidin (Molecular
Probes, Eugene, Oreg.). Enveloped virus particles were stained by
incubating them first with a rabbit polyclonal antiserum that
recognizes the B5R and F13L gene products (21) and then with
rhodamine-conjugated swine antirabbit antibody (Dako Corporation,
Carpinteria, Calif.). Samples were viewed and images were collected
with an MRC 1024 confocal microscope.
 |
RESULTS |
Construction of inducible A33R mutant viruses.
After
unsuccessful attempts to isolate an A33R deletion mutant (cited in
reference 41), construction of a virus containing an
inducible A33R gene was undertaken. The strategy of inserting a 22-bp
lacO sequence just downstream of a late-promoter TAAAT element in a virus (vlacI) that contains a constitutively expressed E. coli lacI has been used to characterize numerous
essential and nonessential genes expressed under late VV promoters
(11, 57, 58). However, for several reasons, the system has
not been used successfully with early promoters.
The first step in designing an inducible A33R mutant was to predict the
type and location of the promoter so that
lacO could
be
correctly positioned. Synthesis of the A33R protein was reported
to
occur predominantly late in infection (
37), and the TAAAT
element of a late promoter is located from

18 to

14 relative
to the
initiation codon of the ORF. Invariably, late RNA synthesis
starts
within the TAAAT; therefore, we decided to place the
lacO sequence just downstream of TAAAT for optimal repression (
19,
57). Further scrutiny, however, revealed the sequence
AAAATATGGAAAACTA,
which resembles the consensus core
sequence of early promoters
(
9), between nucleotides

77
and

62. The finding of two copies
of the early gene transcription
termination sequence, TTTTTNT,
starting 22 bp before and 7 bp after the A33R stop codon, was
also consistent with early expression
(
41,
56). The presence
of the second promoter presented a
dilemma: if early expression
is important, the full promoter region
might be required; on the
other hand, repression might be leaky if
transcription started
from the early promoter, due to both the timing
of expression
and distant location of the promoter relative to
lacO. Therefore
to evaluate the importance of the putative
early promoter, we
made two recombinant viruses, one (vA33full)
containing the full
promoter region and the other (vA33late) containing
a truncated
DNA segment without the predicted early promoter. In each
case,
lacO was positioned adjacent to the late-promoter
TAAAT element.
A recombinant PCR protocol was used to construct the two
different
promoter- and
lacO-modified A33R genes with the
adjacent
gpt selectable
marker and flanking sequences. After
cloning, the sequences of
the relevant parts of the plasmid were
confirmed and the plasmid
was transfected into cells infected with
vlacI for recombination
to occur. Virus was plaque purified in medium
that contained MPA,
to select for
gpt-expressing recombinant
viruses, and IPTG, to
allow expression of the
lacO-controlled A33R gene. After three
plaque purifications,
small virus stocks were prepared and analyzed
by PCR. The sizes of the
PCR products from 11% of the viruses
were consistent with the
insertion of the predicted recombinant
DNA and deletion of WT DNA. The
other virus isolates still retained
the unmodified WT A33R gene,
indicating the presence of single-crossover
recombinants or WT virus.
The relevant portions of the genomes
of WT-A33 (vlacI), vA33full, and
vA33late are depicted in Fig.
1.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 1.
Representation of the genomes of A33R inducible and
deletion mutants. In the top row, relevant features of the genome of
WT-A33 (vlacI) are shown. The A32L, A33R, and A34R ORFs are represented
by ovals, and the tandem early and late promoter elements of the A33R
gene are shown boxed. Arrows indicate the directions of transcription.
In the second row, the genome of vA33full is represented. The locations
of the E. coli gpt gene and lacO are indicated.
The vA33late mutant, depicted in the third row, is similar to vA33full
except that the A33R early promoter has been deleted. The last row
represents part of the genome of vA33 with the neo/GUS
genes replacing A33R.
|
|
Plaque phenotypes of inducible mutant viruses.
The size and
appearance of the plaques formed by the mutant viruses, in the presence
or absence of IPTG, were compared to those of the parental vlacI. The
latter, like vA33full and vA33late, contains the lac
repressor in the TK locus but is designated WT-A33 because the A33R
gene was unmodified. After 29 h, the monolayers were fixed and
stained with crystal violet. The virus retaining only the late promoter
(vA33late) produced small plaques in the absence of IPTG and slightly
larger plaques in the presence of inducer (Fig.
2). Surprisingly, the plaques were
elongated and had the appearance of comets, a phenotype previously
associated with a specific mutation in the A34R gene (4).
The virus containing both the early and late promoters (vA33full)
produced medium-size comet-shaped plaques without IPTG and larger,
normal-size, round plaques with IPTG (Fig. 2).

View larger version (96K):
[in this window]
[in a new window]
|
FIG. 2.
Appearance of plaques formed by A33R inducible mutants.
BS-C-1 cell monolayers were infected with vA33late, vA33full, or WT-A33
virus in the absence (top row) or presence (bottom row) of IPTG. After
29 h, the medium was removed and the monolayers were fixed and
stained with 0.1% crystal violet in 20% ethanol.
|
|
The results demonstrated the importance of the A33R protein in
cell-to-cell spread of VV. The inability of even high concentrations
of
IPTG to induce vA33late to produce large plaques, while the
virus with
both the early and late promoters produced WT-sized
plaques with IPTG,
indicated that the early promoter was important.
Expression of the A33R protein.
The temporal expression of the
A33R gene by WT-A33 and mutant viruses was determined by metabolically
labeling infected cells with [35S]methionine,
immunoprecipitating the A33R protein from the lysates, and analyzing
the protein by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and autoradiography (Fig.
3). In cells infected with WT-A33,
synthesis of the A33R protein was detected at 2 h, suggesting that
the putative early promoter was indeed functional. This is in contrast
to a previous report describing only late A33R expression
(37). The large increase in A33R protein in WT-A33 at
12 h was consistent with the presence of the late promoter consensus element. AraC, an inhibitor of DNA replication and therefore late protein synthesis, decreased A33R levels at 12 h, as
expected. The mutant vA33full synthesized A33R protein at early times,
even in the absence of IPTG, indicating that the early promoter was not
stringently repressed. Nevertheless, there was an increase in A33R
protein expression in the presence of IPTG. In two experiments, the
expression of A33R protein appeared somewhat greater in vA33full than
in WT-A33 at early times, which may be due to an A/T-rich region in the
adjacent gpt sequence in the mutant virus. In cells infected
with the mutant vA33late, no A33R protein was detected at early times,
indicating that the functional early promoter sequence had been
deleted. At 12 h after infection, the A33R protein was detected,
even in the absence of IPTG. Although the amount of protein is only
slightly elevated in the presence of IPTG, this difference is
biologically important, as indicated by the plaque phenotype changes
(Fig. 2). At 12 h postinfection, both mutant viruses made less
A33R protein than WT-A33R did, even in the presence of IPTG, probably
due to negative effects of the lacO sequence adjacent to the
late promoter (58).

View larger version (78K):
[in this window]
[in a new window]
|
FIG. 3.
Synthesis of A33R protein. BS-C-1 cells were infected
with vA33late, vA33full, or WT-A33 virus with IPTG or AraC as
indicated. After 2, 4, 6, or 12 h, the medium was removed, the
cells were incubated for 1 h with [35S]methionine,
and the cells were lysed. The A33R protein was immunoprecipitated with
MAb 4, resolved by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, and autoradiographed. The molecular weights (MW;
103) of markers are shown on the left. The arrows on the
right point to the A33R protein.
|
|
Although we could not obtain stringent repression of this complex
promoter, the experiments demonstrated the presence of a
functional
early promoter regulating expression of the A33R gene.
Moreover, a
comparison of Fig.
2 and
3 suggested a correlation
between the amount
of A33R produced and plaque size and comet
formation. Expression was
the least and the plaques were the smallest
when the early promoter was
deleted and no inducer was added.
We could not, however, distinguish
between the importance of temporal
and quantitative effects of the
early promoter on gene expression.
Construction and characterization of an A33R deletion mutant.
The very small plaques that formed under leaky repressive conditions
suggested that plaques formed in the absence of A33R gene expression
would be even smaller and hence deletion mutants might be exceptionally
difficult to isolate from a large-plaque-forming parental virus. Our
strategy, therefore, was to delete the A33R coding region from
vA33late, which makes very small plaques. In addition, we used both
antibiotic selection to enrich recombinants and a color marker to
identify the plaques.
DNA corresponding to the A32L and the A34R ORFs, flanking the A33R ORF,
were cloned into a plasmid on either side of the genes
coding for
neomycin resistance and the GUS color marker. Upon
recombination, these
genes would replace the A33R promoter and
coding region (as well as the
lacO and the
gpt gene) of vA33late
(Fig.
1). The
DNA encoding the last 14 amino acids of the A33R
ORF was retained so as
not to interfere with the nearby A34R promoter.
This DNA was
transfected into cells infected with vA33late in
the absence of IPTG.
Virus was grown in geneticin, and tiny plaques
staining blue in the
presence of X-Glu were picked and plaque
purified three times. Analysis
of these viruses by PCR indicated
that 3 of 18 viruses (17%) were A33R
deletion mutants; the others
were single-crossover recombinants or
mixtures (data not shown).
One of the deletion mutants was chosen for
further study and named
vA33

. Immunoprecipitation of lysates from
metabolically labeled
cells confirmed the absence of A33R protein from
cells infected
with vA33

, while F13L protein levels appeared normal
(data not
shown). The successful isolation of vA33

indicated that
the A33R
gene is not essential.
The pinpoint plaques produced by vA33

on BS-C-1 cells (shown at
48 h in Fig.
4) were even smaller
than the uninduced vA33late
plaques (shown at 29 h postinfection
in Fig.
2). The plaques exhibited
a comet shape (data not shown)
similar to that of vA33late (Fig.
2). The plaque size of vA33

was
also severely reduced on RK
13 cells, yielding foci of
infection visible as darkly staining points
rather than plaques at
48 h (Fig.
4) and 72 h (data not shown).
These results
suggested that the phenotype is not host dependent.

View larger version (67K):
[in this window]
[in a new window]
|
FIG. 4.
Appearance of plaques formed by the A33R deletion
mutant. BS-C-1 or RK13 monolayers were infected with
WT-A33, vA33 , or vResA33. After 48 h, the medium was removed
and the monolayers were fixed and stained with 0.1% crystal violet in
20% ethanol. At least 30 infectious foci or plaques are present in
each well shown.
|
|
Rescue of the A33R deletion mutant.
When deletion mutants are
made by insertion of a marker gene, the original gene can be restored
to rule out the possibility that the phenotype is due to mutations in
other parts of the genome. However, when the gene is reinserted into
its original location, the procedure does not eliminate the possibility
that either the original deletion itself or the expression of an
inserted marker gene caused the effect via neighboring genes. In the
present situation, this was particularly important because the
neighboring gene, A34R, is required for efficient plaque formation
(11, 31, 55). To avoid such ambiguity, we inserted a new
A33R gene into the distal TK locus of vA33
(replacing the
lacI gene).
The A33R gene was PCR cloned into pSC11 (under the early/late P7.5
promoter) containing the TK flanking regions and the
lacZ gene. Plaques of the rescued virus, vResA33, were identified by
their
blue color in the presence of X-Gal. The vResA33 plaques
were also blue
in the presence of X-Glu, confirming that the virus
was derived from
vA33

. vResA33 was analyzed by PCR for the presence
of
neo/GUS genes in the A33R locus and A33R in the TK locus.
Insertion
of a new A33R gene in a distant locus resulted in plaques
nearly
the size of WT-A33 (Fig.
4), even though the
neo/GUS
genes were
not removed from their position between the A32L and A34R
ORFs.
In addition to vResA33 producing large plaques, it should be
noted
that the vResA33 did not produce comets, indicating that the
comet
phenotype of vA33

is due to the lack of A33R protein and not
an independent mutation elsewhere in the VV genome.
Formation of infectious intracellular and extracellular virus.
Deletion of other genes encoding EEV-specific proteins either increased
or decreased EEV formation (2, 31, 36, 54). To quantitate
the infectious virus produced by vA33
, a one-step growth analysis
was performed. Replicate wells containing BS-C-1 cells were inoculated
with WT-A33 or vA33
and washed after 2 h. At intervals, the
medium and cells were harvested separately and the yields of infectious
virus were determined by plaque assay. In three separate experiments,
the titers of fresh extracellular vA33
virus were two- to fourfold
higher than those of WT-A33 (Fig. 5).
Freeze-thawing was shown to increase the infectivity of A34 deletion
mutant EEV (31). However, disruption of the unpurified
vA33
EEV outer membrane in this manner did not increase the
infectivity, suggesting that the EEV particles are fully infectious. The vA33
mutant produced one-half to one-third of the
cell-associated virus that WT-A33 did; this decrease in production was
similar to the small reduction in IMV that occurs in other EEV protein deletion mutants (31, 36, 54). The total amount of virus produced by vA33
was 35 to 55% of that of WT-A33, since the
majority of virus was cell associated. Similar results were obtained
with BS-C-1 cells, although less vA33
and less WT-A33 were released into the medium than with RK13 cells.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 5.
Yields of extracellular and cell-associated infectious
virus. RK13 cells were infected with WT-A33 or vA33 at a
multiplicity of 10. The inocula were removed after 2 h and
replaced with fresh medium. At the indicated times, the medium was
removed and centrifuged to pellet detached cells. Adherent cells were
scraped into 1 ml of fresh medium and combined with pelleted cells,
frozen, and thawed three times, and sonicated for 30 s. The titers
of the virus from the medium and the cells were determined in duplicate
on BS-C-1 cell monolayers.
|
|
CsCl gradient centrifugation of virus particles.
It was
important to determine whether the extracellular virions produced by
vA33
were enveloped, since IMV could be released by lysis of some
cells. Enveloped virions, either IEV or EEV, can be distinguished from
IMV by their lower buoyant density due to one or two additional
membranes. Infected cells were metabolically labeled with
[35S]methionine, and the virus from the medium and cell
lysates was purified by CsCl density centrifugation. The two peaks of
intracellular particles, corresponding to IMV and IEV from cells
infected with vA33
, were lower than those from cells infected with
WT-A33 (Fig. 6). Analysis of the medium
revealed only a single peak, corresponding to EEV (97%), for both
WT-A33 and vA33
, indicating that IMV contamination in media is
negligible. There was, however, about threefold more EEV produced by
vA33
than by WT-A33 (or vResA33 [data not shown]) and a
corresponding increase in infectivity. Amounts of EEV greater than
those of WT-A33 were also produced by vA33late without inducer (data
not shown). Thus, deletion of the A33R gene increased the amount of
infectious EEV released.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 6.
Purification of wrapped and unwrapped virus particles by
buoyant density centrifugation. [35S]methionine-labeled
WT-A33 or vA33 virus was harvested from the medium, the lysed cells
(intracellular), or intact, washed cells that were trypsin treated to
release virus attached to the cell surface. Virus samples were
centrifuged in CsCl gradients, and the positions of wrapped (wrap) and
unwrapped (un) particles are indicated with arrows.
|
|
Since CEV rather than EEV may be responsible for virus spread to
adjacent cells during plaque formation, we measured the amount
of
[
35S]methionine-labeled virus that could be released from
washed
cells by trypsin (
3). The amounts of labeled material
that
sedimented as enveloped virus were similar for vA33

(Fig.
6),
WT-A33 (Fig.
6), and vResA33 (data not shown). The trypsin also
released some labeled material that remained at the top of the
gradient
and a small amount of material that sedimented as IMV.
Fusion of vA33
-infected cells.
Cells infected with VV can
be induced to fuse by brief treatment with low-pH buffer (10,
20). Formation of wrapped virus is necessary, but not always
sufficient, for acid-induced polykaryon formation (2, 10,
54). We evaluated the ability of vA33
to mediate the formation
of acid-induced syncytia. Cells were infected for 12 h with either
WT-A33 or vA33
, incubated for 2 min in buffer at pH 5.5, and
examined microscopically after 2 and 5 h. As controls, WT-A33
virus-infected cells treated with pH 7.4 buffer and uninfected cells
treated with pH 5.5 buffer showed no fusion. However, by 2 h,
cells infected with either vA33
or WT-A33 virus showed polykaryon
formation, although those of vA33
appeared slightly smaller.
Photographs taken at 5 h are shown in Fig.
7. The A34R and F13L deletion mutant
viruses were also included as controls and induced no cell fusion, as
previously reported (2, 55).

View larger version (145K):
[in this window]
[in a new window]
|
FIG. 7.
Induction of syncytia by WT-A33 or vA33 . BS-C-1 cells
were infected for 12 h, treated for 2 min with buffer at pH 5.5 or
7.4, and then returned to the growth medium for 5 h and examined
by phase-contrast microscopy.
|
|
Electron microscopic examination of cells infected with
vA33
.
The biochemical studies demonstrated that deletion of the
A33R gene reduced the amount of intracellular virus that could be recovered from cell lysates but increased the amount of EEV. Electron microscopy was used to further analyze the effect of the mutation on
morphogenesis. In cells infected with vA33
, immature virions and IMV
appeared to form normally. There also seemed to be an increase in
membrane vesicles. Many of the vA33
IMV were associated with
intracellular membranes, and many appeared to be partially wrapped by a
double membrane (Fig. 8). Fully wrapped
IEV, however, were rare or absent at both 24 and 48 h. In
contrast, completely wrapped IEV were numerous in cells infected with
WT-A33 (Fig. 8) or vResA33 (data not shown). This partial-wrapping
phenotype occurred in both RK13 and BS-C-1 cells infected
with vA33
, as well as with vA33late in the absence of inducer (data
not shown).

View larger version (143K):
[in this window]
[in a new window]
|
FIG. 8.
Electron micrographs of Epon-embedded infected cells.
RK13 cells were infected with WT-A33 or vA33 . After
24 h, the cells were fixed in glutaraldehyde and embedded in Epon.
In WT-A33-infected cells (left panel), the arrow indicates an example
of a fully wrapped IEV particle. In vA33 -infected cells (middle and
right panels) arrows indicate partially wrapped IMV (incomplete IEV).
It is important to note the numerous membrane vesicles with associated
virus particles in the middle panel. Bars, 0.5 µm.
|
|
The increase in vA33

EEV and the apparent lack of fully wrapped IEV
(the presumed precursor) were puzzling. To gain further
insight, we
investigated the membranes seen wrapping vA33

IMV
to determine
whether the membranes contained other proteins known
to localize in the
wrapping membranes derived from the trans-Golgi
compartment
(
43). We labeled the EEV proteins encoded by the
B5R and
F13L genes by using specific antibodies and protein A-gold.
We found
that both proteins were present in the partially wrapped
IEV and the
membranes of extracellular particles released by cells
infected with
vA33

(Fig.
9). These proteins were
also detected
by Western blotting of CsCl-purified vA33

EEV (data
not shown).

View larger version (122K):
[in this window]
[in a new window]
|
FIG. 9.
Immunogold labeling of viral membranes. RK13
cells were infected with WT-A33 or vA33 for 24 h, fixed in
paraformaldehyde, cryosectioned, and incubated with antibodies to the
F13L or B5R EEV-specific proteins and then protein A-gold.
|
|
Detection of actin filaments by immunofluorescence.
Since the
small-plaque phenotype of the vA33
could not be explained by the
failure to form IMV, CEV, or EEV, we investigated VV-induced formation
of specialized actin tails. Infected cells were fixed and stained with
FITC-phalloidin to detect actin filaments and incubated with antibody
to the B5R and F13L membrane proteins to visualize fully or partially
wrapped virus particles (stained red with rhodamine). In uninfected
cells, thin actin stress fibers were visible throughout the cell (Fig.
10). The numerous virus-tipped, thick
actin tails seen in cells infected with WT VV (strain WR) virus were
not present in cells infected with vA33
. Consistent with biochemical
data, fewer virus particles were present in the vA33
-infected cells.
Occasionally, we saw vA33
virus particles adjacent to short, slender
actin filaments but could not determine whether these were true tails.
Also, the perinuclear area staining with VV Golgi-localized proteins
was enlarged in the vA33
-infected cells.

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 10.
Detection of actin filaments in VV-infected cells. HeLa
cells were left uninfected (UN) or were infected with WT VV (strain WR)
or vA33 . At 16 h, the cells were fixed, permeabilized, and
incubated with FITC-conjugated phalloidin and a rabbit polyclonal serum
that recognizes the B5R and F13L proteins, followed by
rhodamine-conjugated antirabbit antibody. The images were examined by
confocal microscopy.
|
|
Scanning electron microscopy.
Virus-tipped, thick,
actin-containing microvilli project from the surfaces of VV-infected
cells (7, 22, 24, 30, 49). These virus-tipped, specialized
microvilli were clearly visible by scanning electron microscopy on the
surfaces of cells infected with WT VV (strain WR) (Fig.
11). In cells infected with vA33
, there were numerous virus particles on the cell surface but they were
not associated with specialized microvilli. Thus, synthesis of the A33R
protein is required for the formation of actin-containing specialized
microvilli and virus spread but not for the transport of virus
particles to the cell surface or the release of EEV.

View larger version (91K):
[in this window]
[in a new window]
|
FIG. 11.
Scanning electron microscopy of cells infected with VV.
HeLa cells were left uninfected (UN) or were infected at a multiplicity
of 10 with WT VV (strain WR) or vA33 . After 17 h, the cells
were fixed with glutaraldehyde and the samples were coated with
gold-palladium alloy and viewed with an Amray 1820D microscope.
|
|
 |
DISCUSSION |
We combined genetic, biochemical, and microscopic approaches to
investigate the role of the A33R glycoprotein, the most recently discovered EEV membrane component (41). Mutants in which the A33R gene promoter was altered or the coding sequence was deleted were
used to demonstrate parallel reductions in A33R glycoprotein synthesis
and plaque size. The presence of an early promoter sequence was
required for normal plaque formation, although it is not known if early
expression is needed or simply contributes quantitatively to the A33R
protein effect. The tiny plaques formed by vA33
were even smaller
than those produced by a B5R deletion mutant (54), approximately the same size as those produced by the A34R and A36R
(31, 36) deletion mutants, but slightly larger than those of
an F13L deletion mutant (3) when compared directly (data not
shown). Small-plaque phenotypes have been associated with reductions in
the quantity (3, 36, 54) or infectivity (31) of
extracellular virus. Neither factor is relevant for the A33R mutant,
since the amounts of infectious EEV were larger than those for WT-A33
controls. In addition, similar amounts of CEV were released by trypsin
treatment of WT-A33- and mutant-infected cells.
Another mechanism of small-plaque formation was recently suggested by
Wolffe et al. (55), who attributed the plaque size of an
A34R deletion mutant to a defect in formation of actin tails and
specialized virus-tipped microvilli. Nevertheless, the reported lower infectivity of A34R mutant EEV (31) may also have
contributed to impaired cell-to-cell spread. vA33
is the first
small-plaque mutant virus that produces normal levels of fully
infectious EEV and CEV. vA33
has defects in actin tail formation and
specialized microvilli, providing strong support for a model in which
efficient cell-to-cell spread is mediated by virus particles at the
tips of specialized microvilli.
The inability to detect actin tails by microscopy in cells infected
with the A33R deletion mutant is apparently due to their failure to
form, although the transient existence of tails cannot be ruled out.
The A33R proteins might have direct or indirect roles in the actin
nucleation or polymerization steps. In cells infected with A33R or A34R
(11, 55) deletion mutants, there appeared to be a paucity of
fully wrapped cytoplasmic particles to which actin tails could attach.
Although there are many partially wrapped IEV in cells infected with
the A33R deletion mutant, actin tails are not seen. Thus, either the
A33R protein or fully closed IEV are required for attachment of actin
tails. Therefore, the absence of actin tails and specialized microvilli
may be secondary to a reduction in fully wrapped IEV.
Some strains of VV, such as IHD, form plaques under liquid medium that
have an elongated comet shape (for an example, see Fig. 2). Comets are
associated with increased amounts of EEV and with a single amino acid
substitution in the A34R ORF (3, 4). In the absence of WT
levels of A33R protein, the small plaques of A33R mutants had comet
tails. Tiny comets were detected with vA33
, but larger comets were
found with the leaky inducible mutants. vA33full, however, produced
round plaques without comets in the presence of IPTG, indicating that
comet formation was due to reduced A33R protein levels rather than a
coincidental mutation elsewhere in the genome. Nevertheless, the
proximity of the A34R gene, which also encodes an EEV membrane
glycoprotein associated with comet formation, made it necessary to
consider indirect effects caused by the genetic alterations at the A33R
locus. To evaluate this potential problem, we inserted a new A33R gene
into a distal site within the genome of vA33
. The rescued virus
formed large plaques without comets, despite retention of the
alterations at the site of the original A33R gene. Therefore, we could
confidently rule out significant neighboring gene effects on the mutant
phenotype. Since a risk of local disturbances at deletion or insertion
sites occurs frequently, distal gene insertion may be a generally
useful alternative to constructing revertants. Comets appear to form when the amounts of infectious EEV are increased. It is also possible that the A33R and A34R proteins might be involved in other ways, e.g.,
in the binding and release of the virus particles from the cell
surface.
Cells infected with VV can be induced to fuse by brief low-pH treatment
(10, 20), suggesting that one mechanism of virus entry is
endosomal (26). The assembly inhibitor rifampin or deletion
of the F13L or B5R gene inhibits fusion, presumably due to the absence
of CEV on the cell surface (2, 10, 54). The failure of A34R
deletion mutants to induce fusion suggests that actin-containing
microvilli might be required (55). However, microvilli are
not required since vA33
induced fusion without specialized
microvilli. It is likely, therefore, that in the case of the A34R
deletion mutant, either CEV are not present on the surface of infected
cells or the particles are not competent to fuse.
Fully wrapped IEV were rare or absent in vA33
-infected cells,
whereas partially enveloped IMV were numerous. This seemed paradoxical
since large amounts of EEV were produced. The partially wrapped IMV
could represent (i) the form that fuses with the membrane to release
EEV, (ii) intermediate forms that would become completely wrapped, or
(iii) dead-end structures resulting from defective wrapping machinery.
If partially enveloped IMV fuse with the plasma membrane (hypothesis
i), this could raise topological problems and lead to incomplete or
missing EEV membranes. If the incomplete IMV do eventually become fully
wrapped (hypothesis ii), then the fully wrapped A33R-deficient IEV must
exit the cells very rapidly so they are not captured by electron
microscopy. In that scenario, one role of the A33R protein may be to
retard the transit of IEV in order to permit actin tails to form. If
the incompletely wrapped IMV are dead-end structures (hypothesis iii),
this would suggest that the A33R protein is needed for complete
wrapping and that there must be alternative pathways of EEV formation,
such as budding through Golgi or plasma membranes, both of which
contain EEV-specific proteins (43). Although budding
particles are not commonly seen, virus particles are sometimes found
inside of membrane cisternae, and Tsutsui et al. (50, 51)
described plasma membrane budding of the IHD-W strain of VV in FL
cells. Budding as well as wrapping and fusion mechanisms would result
in EEV that have one additional membrane relative to those of IMV.
In conclusion, the A33R protein is required for normal plaque
formation, actin tails, and specialized virus-tipped microvilli. These
data indicate that the formation of EEV and CEV is not sufficient for
plaque formation and suggest that the microvilli are responsible for
efficient cell-to-cell spread.
 |
ACKNOWLEDGMENTS |
We thank T. Shors for the pZippy neo/GUS vector, N. Cooper for cells, and J. Sisler for sequencing of plasmids.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Building 4, Room
229, 4 Center Dr., MSC 0445, National Institutes of Health, MD
20892-0445. Phone: (301) 496-9869. Fax: (301) 480-1147. E-mail:
bmoss{at}nih.gov.
 |
REFERENCES |
| 1.
|
Appleyard, G.,
A. J. Hapel, and E. A. Boulter.
1971.
An antigenic difference between intracellular and extracellular rabbitpox virus.
J. Gen. Virol.
13:9-17[Abstract/Free Full Text].
|
| 2.
|
Blasco, R., and B. Moss.
1991.
Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-dalton outer envelope protein.
J. Virol.
65:5910-5920[Abstract/Free Full Text].
|
| 3.
|
Blasco, R., and B. Moss.
1992.
Role of cell-associated enveloped vaccinia virus in cell-to-cell spread.
J. Virol.
66:4170-4179[Abstract/Free Full Text].
|
| 4.
|
Blasco, R.,
J. R. Sisler, and B. Moss.
1993.
Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene.
J. Virol.
67:3319-3325[Abstract/Free Full Text].
|
| 5.
|
Boulter, E. A., and G. Appleyard.
1973.
Differences between extracellular and intracellular forms of poxvirus and their implications.
Prog. Med. Virol.
16:86-108[Medline].
|
| 6.
|
Carroll, M. W., and B. Moss.
1995.
E. coli -glucuronidase (GUS) as a marker for recombinant vaccinia viruses.
BioTechniques
19:352-354.
[Medline] |
| 7.
|
Cudmore, S.,
P. Cossart,
G. Griffiths, and M. Way.
1995.
Actin-based motility of vaccinia virus.
Nature
378:636-638[Medline].
|
| 8.
|
Dales, S., and L. Siminovitch.
1961.
The development of vaccinia virus in Earles L strain cells as examined by electron microscopy.
J. Biophys. Biochem. Cytol.
10:475-503.
[Abstract/Free Full Text] |
| 9.
|
Davison, A. J., and B. Moss.
1989.
The structure of vaccinia virus early promoters.
J. Mol. Biol.
210:749-769[Medline].
|
| 10.
|
Doms, R. W.,
R. Blumenthal, and B. Moss.
1990.
Fusion of intra- and extracellular forms of vaccinia virus with the cell membrane.
J. Virol.
64:4884-4892[Abstract/Free Full Text].
|
| 11.
|
Duncan, S. A., and G. L. Smith.
1992.
Identification and characterization of an extracellular envelope glycoprotein affecting vaccinia virus egress.
J. Virol.
66:1610-1621[Abstract/Free Full Text].
|
| 12.
|
Earl, P. L.,
N. Cooper, and B. Moss.
1991.
Preparation of cell cultures and vaccinia virus stocks, p. 16.16.1-16.16.7.
In
F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol. 2. Wiley Interscience, New York, N.Y.
|
| 13.
|
Eisenlohr, L. C.,
I. Bacik,
J. R. Bennink,
K. Bernstein, and J. W. Yewdell.
1992.
Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T lymphocytes.
Cell
71:963-969[Medline].
|
| 14.
|
Engelstad, M.,
S. T. Howard, and G. L. Smith.
1992.
A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope.
Virology
188:801-810[Medline].
|
| 15.
|
Engelstad, M., and G. L. Smith.
1993.
The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence.
Virology
194:627-637[Medline].
|
| 16.
|
Falkner, F. G., and B. Moss.
1988.
Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors.
J. Virol.
62:1849-1854[Abstract/Free Full Text].
|
| 17.
|
Fenner, F.,
D. A. Henderson,
I. Arita,
Z. Jezek, and I. D. Ladnyi.
1988.
In
Smallpox and its eradication, 1st ed.
World Health Organization, Geneva, Switzerland.
|
| 18.
|
Franke, C. A.,
C. M. Rice,
J. H. Strauss, and D. E. Hruby.
1985.
Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants.
Mol. Cell. Biol.
5:1918-1924[Abstract/Free Full Text].
|
| 19.
|
Fuerst, T. R.,
M. P. Fernandez, and B. Moss.
1989.
Transfer of the inducible lac repressor/operator system from Escherichia coli to a vaccinia virus expression vector.
Proc. Natl. Acad. Sci. USA
86:2549-2553[Abstract/Free Full Text].
|
| 20.
|
Gong, S. C.,
C. F. Lai, and M. Esteban.
1990.
Vaccinia virus induces cell fusion at acid pH and this activity is mediated by the N-terminus of the 14-kDa virus envelope protein.
Virology
178:81-91[Medline].
|
| 21.
|
Hiller, G.,
H. Eibl, and K. Weber.
1981.
Characterization of intracellular and extracellular vaccinia virus variants: N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine interferes with cytoplasmic virus dissemination and release.
J. Virol.
39:903-913[Abstract/Free Full Text].
|
| 22.
|
Hiller, G.,
C. Jungwirth, and K. Weber.
1981.
Fluorescence microscopical analysis of the life cycle of vaccinia virus in chick embryo fibroblasts. Virus-cytoskeleton interactions.
Exp. Cell Res.
132:81-87[Medline].
|
| 23.
|
Hiller, G., and K. Weber.
1985.
Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment.
J. Virol.
55:651-659[Abstract/Free Full Text].
|
| 24.
|
Hiller, G.,
K. Weber,
L. Schneider,
C. Parajsz, and C. Jungwirth.
1979.
Interaction of assembled progeny pox viruses with the cellular cytoskeleton.
Virology
98:142-153[Medline].
|
| 25.
|
Hirt, P.,
G. Hiller, and R. Wittek.
1986.
Localization and fine structure of a vaccinia virus gene encoding an envelope antigen.
J. Virol.
58:757-764[Abstract/Free Full Text].
|
| 26.
|
Ichihashi, Y., and S. Dales.
1971.
Biogenesis of poxviruses: interrelationship between hemagglutinin production and polykaryocytosis.
Virology
46:533-543[Medline].
|
| 27.
|
Ichihashi, Y.,
S. Matsumoto, and S. Dales.
1971.
Biogenesis of poxviruses: role of A-type inclusions and host cell membranes in virus dissemination.
Virology
46:507-532[Medline].
|
| 28.
| Isaacs, S., R. Blasco, and B. Moss. Unpublished
data.
|
| 29.
|
Isaacs, S. N.,
E. J. Wolffe,
L. Payne, and B. Moss.
1992.
Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope.
J. Virol.
66:7217-7224[Abstract/Free Full Text].
|
| 30.
|
Krempien, U.,
L. Schneider,
G. Hiller,
K. Weber,
E. Katz, and C. Jungwirth.
1981.
Conditions for pox virus-specific microvilli formation studied during synchronized virus assembly.
Virology
113:556-564[Medline].
|
| 31.
|
McIntosh, A. G., and G. L. Smith.
1996.
Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus.
J. Virol.
70:272-281[Abstract].
|
| 32.
|
Morgan, C.
1976.
Vaccinia virus reexamined: development and release.
Virology
73:43-58[Medline].
|
| 33.
|
Moss, B.
1996.
Poxviridae: the viruses and their replication.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. Lippincott-Raven Press, New York, N.Y.
|
| 34.
|
Moss, B.
1991.
Vaccinia virus: a tool for research and vaccine development.
Science
252:1662-1667[Abstract/Free Full Text].
|
| 35.
|
Mukinda, V. B.,
G. Mwema,
M. Kilundu,
D. L. Heymann,
A. S. Khan, and J. J. Esposito.
1997.
Re-emergence of human monkeypox in Zaire in 1996.
Lancet
17:1449-1450.
|
| 36.
|
Parkinson, J. E., and G. L. Smith.
1994.
Vaccinia virus gene A36R encodes a M(r) 43-50 K protein on the surface of extracellular enveloped virus.
Virology
204:376-390[Medline].
|
| 37.
|
Payne, L. G.
1992.
Characterization of vaccinia virus glycoproteins by monoclonal antibody preparations.
Virology
187:251-260[Medline].
|
| 38.
|
Payne, L. G.
1980.
Significance of extracellular virus in the in vitro and in vivo dissemination of vaccinia virus.
J. Gen. Virol.
31:147-155.
|
| 39.
|
Payne, L. G., and K. Kristensson.
1979.
Mechanism of vaccinia virus release and its specific inhibition by N1-isonicatinoyl-N2-3-methyl-4-chlorobenzoylhydrazine.
J. Virol.
32:614-622[Abstract/Free Full Text].
|
| 40.
|
Payne, L. G., and E. Norrby.
1976.
Presence of haemagglutinin in the envelope of extracellular vaccinia virus particles.
J. Gen. Virol.
32:63-72[Abstract/Free Full Text].
|
| 41.
|
Roper, R. L.,
L. G. Payne, and B. Moss.
1996.
Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene.
J. Virol.
70:3753-3762[Abstract].
|
| 42.
| Schmaljohn, A. Personal communication.
|
| 43.
|
Schmelz, M.,
B. Sodeik,
M. Ericsson,
E. J. Wolffe,
H. Shida,
G. Hiller, and G. Griffiths.
1994.
Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network.
J. Virol.
68:130-147[Abstract/Free Full Text].
|
| 44.
|
Seki, M.,
M. Oie,
Y. Ichihashi, and H. Shida.
1990.
Hemadsorption and fusion inhibition activities of hemaggluttinin analyzed by vaccinia virus mutants.
Virology
175:372-384[Medline].
|
| 45.
|
Senkevich, T. G.,
J. J. Bugert,
J. R. Sisler,
E. V. Koonin,
G. Darai, and B. Moss.
1996.
Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes.
Science
273:813-816[Abstract].
|
| 46.
|
Shida, H.
1986.
Nucleotide sequence of the vaccinia virus hemagglutinin gene.
Virology
150:451-462[Medline].
|
| 47.
| Shors, T., and B. Moss. Unpublished data.
|
| 48.
|
Sodeik, B.,
R. W. Doms,
M. Ericcson,
G. Hiller,
C. E. Machamer,
W. van't Hof,
G. van Meer,
B. Moss, and G. Griffiths.
1993.
Assembly of vaccinia virus: role of the intermediate compartment between the endoplasmic reticulum and the Golgi stacks.
J. Cell Biol.
121:521-541[Abstract/Free Full Text].
|
| 49.
|
Stokes, G. V.
1976.
High-voltage electron microscope study of the release of vaccinia virus from whole cells.
J. Virol.
18:636-643[Abstract/Free Full Text].
|
| 50.
|
Tsutsui, K.
1983.
Release of vaccinia virus from FL cells infected with the IHD-W strain.
J. Electron Microsc.
32:125-140[Abstract/Free Full Text].
|
| 51.
|
Tsutsui, K.,
F. Uno,
K. Akatsuka, and S. Nii.
1983.
Electron microscopic study on vaccinia virus release.
Arch. Virol.
75:213-218[Medline].
|
| 52.
|
Turner, G. S., and E. J. Squires.
1971.
Inactivated smallpox vaccine: immunogenicity of inactivated intracellular and extracellular vaccinia virus.
J. Gen. Virol.
13:19-25[Abstract/Free Full Text].
|
| 53.
|
Turner, P. C., and R. W. Moyer.
1992.
A PCR-based method for manipulation of the vaccinia virus genome that eliminates the need for cloning.
BioTechniques
13:764-771.
[Medline] |
| 54.
|
Wolffe, E. J.,
S. N. Isaacs, and B. Moss.
1993.
Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination.
J. Virol.
67:4732-4741[Abstract/Free Full Text].
|
| 55.
|
Wolffe, E. J.,
E. Katz,
A. Weisberg, and B. Moss.
1997.
The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus.
J. Virol.
71:3904-3915[Abstract].
|
| 56.
|
Yuen, L., and B. Moss.
1987.
Oligonucleotide sequence signalling transcriptional termination of vaccinia virus early genes.
Proc. Natl. Acad. Sci. USA
84:6417-6421[Abstract/Free Full Text].
|
| 57.
|
Zhang, Y., and B. Moss.
1991.
Inducer-dependent conditional-lethal mutant animal viruses.
Proc. Natl. Acad. Sci. USA
88:1511-1515[Abstract/Free Full Text].
|
| 58.
|
Zhang, Y., and B. Moss.
1991.
Vaccinia virus morphogenesis interrupted when expression of the gene encoding an 11-kilodalton phosphoprotein is prevented by the Escherichia coli lac repressor.
J. Virol.
65:6101-6110[Abstract/Free Full Text].
|
J Virol, May 1998, p. 4192-4204, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Domi, A., Weisberg, A. S., Moss, B.
(2008). Vaccinia Virus E2L Null Mutants Exhibit a Major Reduction in Extracellular Virion Formation and Virus Spread. J. Virol.
82: 4215-4226
[Abstract]
[Full Text]
-
Earley, A. K., Chan, W. M., Ward, B. M.
(2008). The Vaccinia Virus B5 Protein Requires A34 for Efficient Intracellular Trafficking from the Endoplasmic Reticulum to the Site of Wrapping and Incorporation into Progeny Virions. J. Virol.
82: 2161-2169
[Abstract]
[Full Text]
-
Perdiguero, B., Lorenzo, M. M., Blasco, R.
(2008). Vaccinia Virus A34 Glycoprotein Determines the Protein Composition of the Extracellular Virus Envelope. J. Virol.
82: 2150-2160
[Abstract]
[Full Text]
-
Garcia, A. D., Meseda, C. A., Mayer, A. E., Kumar, A., Merchlinsky, M., Weir, J. P.
(2007). Characterization and Use of Mammalian-Expressed Vaccinia Virus Extracellular Membrane Proteins for Quantification of the Humoral Immune Response to Smallpox Vaccines. CVI
14: 1032-1044
[Abstract]
[Full Text]
-
Perdiguero, B., Blasco, R.
(2006). Interaction between Vaccinia Virus Extracellular Virus Envelope A33 and B5 Glycoproteins.. J. Virol.
80: 8763-8777
[Abstract]
[Full Text]
-
Afonso, C. L., Tulman, E. R., Delhon, G., Lu, Z., Viljoen, G. J., Wallace, D. B., Kutish, G. F., Rock, D. L.
(2006). Genome of crocodilepox virus.. J. Virol.
80: 4978-4991
[Abstract]
[Full Text]
-
Law, M., Carter, G. C., Roberts, K. L., Hollinshead, M., Smith, G. L.
(2006). From the Cover: Ligand-induced and nonfusogenic dissolution of a viral membrane. Proc. Natl. Acad. Sci. USA
103: 5989-5994
[Abstract]
[Full Text]
-
Roper, R. L.
(2006). Characterization of the Vaccinia Virus A35R Protein and Its Role in Virulence. J. Virol.
80: 306-313
[Abstract]
[Full Text]
-
Townsley, A. C., Senkevich, T. G., Moss, B.
(2005). Vaccinia Virus A21 Virion Membrane Protein Is Required for Cell Entry and Fusion. J. Virol.
79: 9458-9469
[Abstract]
[Full Text]
-
Favoreel, H. W., Van Minnebruggen, G., Adriaensen, D., Nauwynck, H. J.
(2005). Cytoskeletal rearrangements and cell extensions induced by the US3 kinase of an alphaherpesvirus are associated with enhanced spread. Proc. Natl. Acad. Sci. USA
102: 8990-8995
[Abstract]
[Full Text]
-
Guerra, S., Aracil, M., Conde, R., Bernad, A., Esteban, M.
(2005). Wiskott-Aldrich Syndrome Protein Is Needed for Vaccinia Virus Pathogenesis. J. Virol.
79: 2133-2140
[Abstract]
[Full Text]
-
Ward, B. M., Moss, B.
(2004). Vaccinia Virus A36R Membrane Protein Provides a Direct Link between Intracellular Enveloped Virions and the Microtubule Motor Kinesin. J. Virol.
78: 2486-2493
[Abstract]
[Full Text]
-
Katz, E., Ward, B. M., Weisberg, A. S., Moss, B.
(2003). Mutations in the Vaccinia Virus A33R and B5R Envelope Proteins That Enhance Release of Extracellular Virions and Eliminate Formation of Actin-Containing Microvilli without Preventing Tyrosine Phosphorylation of the A36R Protein. J. Virol.
77: 12266-12275
[Abstract]
[Full Text]
-
Ward, B. M., Weisberg, A. S., Moss, B.
(2003). Mapping and Functional Analysis of Interaction Sites within the Cytoplasmic Domains of the Vaccinia Virus A33R and A36R Envelope Proteins. J. Virol.
77: 4113-4126
[Abstract]
[Full Text]
-
Smith, G. L., Vanderplasschen, A., Law, M.
(2002). The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol.
83: 2915-2931
[Abstract]
[Full Text]
-
Katz, E., Wolffe, E., Moss, B.
(2002). Identification of Second-Site Mutations That Enhance Release and Spread of Vaccinia Virus. J. Virol.
76: 11637-11644
[Abstract]
[Full Text]
-
Krauss, O., Hollinshead, R., Hollinshead, M., Smith, G. L.
(2002). An investigation of incorporation of cellular antigens into vaccinia virus particles. J. Gen. Virol.
83: 2347-2359
[Abstract]
[Full Text]
-
Husain, M., Moss, B.
(2002). Similarities in the Induction of Post-Golgi Vesicles by the Vaccinia Virus F13L Protein and Phospholipase D. J. Virol.
76: 7777-7789
[Abstract]
[Full Text]
-
Rodger, G., Smith, G. L.
(2002). Replacing the SCR domains of vaccinia virus protein B5R with EGFP causes a reduction in plaque size and actin tail formation but enveloped virions are still transported to the cell surface. J. Gen. Virol.
83: 323-332
[Abstract]
[Full Text]
-
Johnson, D. C., Huber, M. T.
(2002). Directed Egress of Animal Viruses Promotes Cell-to-Cell Spread. J. Virol.
76: 1-8
[Full Text]
-
van Eijl, H., Hollinshead, M., Rodger, G., Zhang, W.-H., Smith, G. L.
(2002). The vaccinia virus F12L protein is associated with intracellular enveloped virus particles and is required for their egress to the cell surface. J. Gen. Virol.
83: 195-207
[Abstract]
[Full Text]
-
Law, M., Hollinshead, R., Smith, G. L.
(2002). Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread. J. Gen. Virol.
83: 209-222
[Abstract]
[Full Text]
-
Goldberg, M. B.
(2001). Actin-Based Motility of Intracellular Microbial Pathogens. Microbiol. Mol. Biol. Rev.
65: 595-626
[Abstract]
[Full Text]
-
Ward, B. M., Moss, B.
(2001). Vaccinia Virus Intracellular Movement Is Associated with Microtubules and Independent of Actin Tails. J. Virol.
75: 11651-11663
[Abstract]
[Full Text]
-
Husain, M., Moss, B.
(2001). Vaccinia Virus F13L Protein with a Conserved Phospholipase Catalytic Motif Induces Colocalization of the B5R Envelope Glycoprotein in Post-Golgi Vesicles. J. Virol.
75: 7528-7542
[Abstract]
[Full Text]
-
Hollinshead, M., Rodger, G., Van Eijl, H., Law, M., Hollinshead, R., Vaux, D. J.T., Smith, G. L.
(2001). Vaccinia virus utilizes microtubules for movement to the cell surface. JCB
154: 389-402
[Abstract]
[Full Text]
-
Ward, B. M., Moss, B.
(2001). Visualization of Intracellular Movement of Vaccinia Virus Virions Containing a Green Fluorescent Protein-B5R Membrane Protein Chimera. J. Virol.
75: 4802-4813
[Abstract]
[Full Text]
-
Mathew, E. C., Sanderson, C. M., Hollinshead, R., Smith, G. L.
(2001). A mutational analysis of the vaccinia virus B5R protein. J. Gen. Virol.
82: 1199-1213
[Abstract]
[Full Text]
-
Wolffe, E. J., Weisberg, A. S., Moss, B.
(2001). The Vaccinia Virus A33R Protein Provides a Chaperone Function for Viral Membrane Localization and Tyrosine Phosphorylation of the A36R Protein. J. Virol.
75: 303-310
[Abstract]
[Full Text]
-
Zhang, W.-H., Wilcock, D., Smith, G. L.
(2000). Vaccinia Virus F12L Protein Is Required for Actin Tail Formation, Normal Plaque Size, and Virulence. J. Virol.
74: 11654-11662
[Abstract]
[Full Text]
-
Lorenzo, M. M., Galindo, I., Griffiths, G., Blasco, R.
(2000). Intracellular Localization of Vaccinia Virus Extracellular Enveloped Virus Envelope Proteins Individually Expressed Using a Semliki Forest Virus Replicon. J. Virol.
74: 10535-10550
[Abstract]
[Full Text]
-
Yeh, W. W., Moss, B., Wolffe, E. J.
(2000). The Vaccinia Virus A9L Gene Encodes a Membrane Protein Required for an Early Step in Virion Morphogenesis. J. Virol.
74: 9701-9711
[Abstract]
[Full Text]
-
da Fonseca, F. G., Wolffe, E. J., Weisberg, A., Moss, B.
(2000). Effects of Deletion or Stringent Repression of the H3L Envelope Gene on Vaccinia Virus Replication. J. Virol.
74: 7518-7528
[Abstract]
[Full Text]
-
Ward, B. M., Moss, B.
(2000). Golgi Network Targeting and Plasma Membrane Internalization Signals in Vaccinia Virus B5R Envelope Protein. J. Virol.
74: 3771-3780
[Abstract]
[Full Text]
-
Stidwill, R. P., Greber, U. F.
(2000). Intracellular Virus Trafficking Reveals Physiological Characteristics of the Cytoskeleton. Physiology
15: 67-71
[Abstract]
[Full Text]
-
Boulanger, D., Smith, T., Skinner, M. A.
(2000). Morphogenesis and release of fowlpox virus. J. Gen. Virol.
81: 675-687
[Abstract]
[Full Text]
-
Sanderson, C. M., Hollinshead, M., Smith, G. L.
(2000). The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles. J. Gen. Virol.
81: 47-58
[Abstract]
[Full Text]
-
Betakova, T., Wolffe, E. J., Moss, B.
(1999). Regulation of Vaccinia Virus Morphogenesis: Phosphorylation of the A14L and A17L Membrane Proteins and C-Terminal Truncation of the A17L Protein Are Dependent on the F10L Kinase. J. Virol.
73: 3534-3543
[Abstract]
[Full Text]
-
Röttger, S., Frischknecht, F., Reckmann, I., Smith, G. L., Way, M.
(1999). Interactions between Vaccinia Virus IEV Membrane Proteins and Their Roles in IEV Assembly and Actin Tail Formation. J. Virol.
73: 2863-2875
[Abstract]
[Full Text]
-
Roper, R. L., Moss, B.
(1999). Envelope Formation Is Blocked by Mutation of a Sequence Related to the HKD Phospholipid Metabolism Motif in the Vaccinia Virus F13L Protein. J. Virol.
73: 1108-1117
[Abstract]
[Full Text]
-
Sanderson, C. M., Smith, G. L.
(1998). Vaccinia Virus Induces Ca2+-Independent Cell-Matrix Adhesion during the Motile Phase of Infection. J. Virol.
72: 9924-9933
[Abstract]
[Full Text]
-
Dingwell, K. S., Johnson, D. C.
(1998). The Herpes Simplex Virus gE-gI Complex Facilitates Cell-to-Cell Spread and Binds to Components of Cell Junctions. J. Virol.
72: 8933-8942
[Abstract]
[Full Text]